UnitedHealth’s Medicare Advantage Crisis Is a Systemic Red Flag for Risk Coding and Digital Health Alignment

UnitedHealth Group’s recent stock nosedive and the reported criminal investigation into its Medicare Advantage (MA) billing practices have triggered urgent questions about the structural incentives behind Medicare’s most commercially successful program. According to reporting from The Wall Street Journal, the Department of Justice has been investigating UnitedHealth’s use of diagnosis coding practices within its MA plans since mid-2023, focusing on whether the insurer exaggerated patient conditions to increase federal payments (source).

The company, which has denied being formally notified of the probe, lost more than $110 billion in market value over eight trading sessions and replaced its CEO while suspending its 2025 guidance. Shares of Elevance Health, Humana and CVS Health also fell sharply, reflecting industry-wide concern about increased scrutiny of MA practices.

But the root problem is not limited to one company. The MA model has become fundamentally intertwined with a digital and actuarial system that rewards diagnostic intensity over clinical integrity.

Medicare Advantage’s Incentive Architecture

Under the current MA risk adjustment formula, insurers receive higher payments for patients who are sicker based on submitted diagnosis codes. These codes are supposed to reflect true clinical conditions. However, several whistleblower cases and government audits have revealed a pattern: insurers routinely deploy aggressive chart reviews and use predictive algorithms to identify “suspected” conditions, which can be documented and submitted to inflate reimbursement.

A 2022 report from the Office of Inspector General found that nine out of ten MA plans were using chart reviews and health risk assessments to boost risk scores, with minimal evidence of follow-up care for those newly documented conditions (source). This gap between documentation and care delivery raises major concerns about clinical relevance and accountability.

UnitedHealth is not an outlier. In the past five years, multiple insurers including Cigna, Anthem and Kaiser have faced allegations or settlements related to similar practices. The Department of Justice has consistently flagged these billing patterns as fertile ground for fraud, particularly because of the opacity of algorithmically generated risk profiles.

At stake is the credibility of Medicare Advantage as a care coordination model. When diagnosis inflation becomes a profit strategy, the model moves away from patient-centered care and toward data manipulation.

Digital Health’s Complicity in the Coding Economy

The risk adjustment infrastructure has become deeply embedded within the digital health stack. Natural language processing tools, AI-driven condition flaggers and remote patient monitoring dashboards are increasingly optimized not for care quality, but for identifying and submitting reimbursable diagnoses.

Companies such as Apixio, which markets AI for “risk adjustment accuracy,” and Innovaccer, which offers condition suspecting tools to MA plans, are reshaping clinical data into a coding opportunity. While marketed as clinical support, these tools often lack rigorous oversight to ensure they enhance actual care rather than billing volume (source).

A 2023 Health Affairs study found that algorithmically identified conditions were often coded without subsequent treatment or care planning. This disconnect between what is documented and what is delivered undermines both the patient experience and the clinical mission (source).

The problem compounds clinician burnout. Primary care physicians in MA-heavy markets report persistent pressure from payers and employer groups to confirm pre-flagged conditions during patient visits. These expectations convert clinical encounters into transactional opportunities for documentation, eroding physician autonomy and patient trust.

From Risk Optimization to Clinical Alignment

To restore integrity to MA and the digital tools that support it, policy and industry stakeholders must aggressively realign incentives. This includes:

1. Independent clinical validation of AI-detected conditions: Suspected diagnoses flagged by software should not be submitted for reimbursement without physician review and corroborating clinical evidence.

2. Transparency around digital tools used in coding: CMS and state regulators should require MA plans to disclose the specific AI and chart review tools used in risk adjustment, including their validation metrics and clinical audit processes.

3. Linking risk coding to actual care delivery: Payment increases based on higher risk scores should be contingent upon documented follow-up care, not merely the presence of a code in the record.

CMS has signaled intent to act. In 2023, it finalized a rule limiting how MA plans can use health risk assessments to generate codes and is piloting audits that compare risk score accuracy across different submission methods (source). However, enforcement remains spotty, and the coding ecosystem has outpaced the regulatory response.

Ultimately, the MA crisis is not about one company’s compliance breach. It is about an ecosystem where care documentation has eclipsed care delivery.

For digital health to be a partner in value-based care rather than a conduit for risk inflation, it must shed its fixation on coding optimization and return to the core clinical mission. If we fail to close the gap between what is coded and what is cared for, Medicare Advantage will remain profitable but hollow.

And the next criminal probe will not be an outlier. It will be the norm.